Pomerantz Law Firm Investigates Regeneron Pharmaceuticals Over Clinical Trial Results
The Pomerantz Law Firm is investigating potential securities fraud at Regeneron Pharmaceuticals following the announcement of negative Phase 3 trial results for a key drug combination. The news caused Regeneron's stock to drop nearly 10%.
Tickers: $REGN
Topics: clinical_trial_results pharmaceuticals stock_price_drop